Skip to Content

AHA: Mavacamten May Treat Hypertrophic Cardiomyopathy

THURSDAY, Nov. 12, 2020 -- Compared with placebo, mavacamten (Mava), a novel inhibitor of cardiac myosin, for 30 weeks leads to improvement in left ventricular (LV) hypertrophy and markers of left-sided filling pressures in patients with obstructive hypertrophic cardiomyopathy (oHCM), according to a study presented at the American Heart Association Scientific Sessions 2020, held virtually from Nov. 13 to 17.

Sheila M. Hegde, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues examined the effect of Mava on focused measures of cardiac structure and function in oHCM in a double-blind, placebo-controlled phase 3 trial. Symptomatic oHCM patients were randomly assigned to either Mava or placebo for 30 weeks in a 1:1 ratio; 244 patients completed the study.

The researchers found that 30-week treatment with Mava led to significant reductions in left arterial volume index, lateral E/e', septal E/e'. and LV mass index compared with placebo. Significantly more patients treated with Mava than placebo achieved resolution of mitral valve systolic anterior motion and mitral regurgitation (80.9 versus 34.0 percent and 9.0 versus 0.0 percent, respectively).

"These findings reinforced and extended data from prior open label trials. Additional changes in measures of cardiac structure and function were also observed, including reduction in the size of the left atrium," Hedge said in a statement. "Together, these results reflect this medication's impact on the underlying pathophysiology of hypertrophic cardiomyopathy. A long-term extension trial is ongoing and will provide additional insight on the long-term impact on cardiac structure and function."

Several authors disclosed financial ties to pharmaceutical companies, including MyoKardia, which is developing mavacamten and funded the study.

Press Release

More Information

© 2021 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Referrals for Acute Heart Failure Dropped During COVID-19

FRIDAY, Jan. 15, 2021 -- In the eight weeks following the first reported U.K. death due to COVID-19, there was a decrease in referral of patients with acute heart failure, with a...

Fracking Activity May Up Heart Failure Hospitalization Risk

TUESDAY, Dec. 8, 2020 -- For patients with heart failure, environmental exposures to three of four phases of unconventional natural gas development (UNGD) are associated with...

Sedentary Behavior Linked to Heart Failure Hospitalization

THURSDAY, Dec. 3, 2020 -- In postmenopausal women, sedentary behavior is associated with an increased risk for incident heart failure hospitalization, according to a study...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.